Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the symptomatic effects of Coenzyme Q10 nanodispersed
solution in middle-stage Parkinson's disease (PD) patients (Hoehn&Yahr II to III). The
treatment phase includes three months period of 300 mg Coenzyme Q10 per day or placebo.
The primary outcome measure was the combined Unified Parkinson's Disease Rating Scale (UPDRS)
Part II and III.
The hypothesis of this study was that Coenzyme Q10 improves the energy status of the diseased
dopaminergic neuronal cell type and thus producing more dopamine leading to an improvement of
parkinsonian symptoms in PD patients.
Phase:
Phase 3
Details
Lead Sponsor:
Technische Universität Dresden
Collaborators:
Deutsche Parkinson-Vereinigung e.V. MSE Pharmazeutika GmbH, Bad Homburg